MedTrace Logo

IOP and Medication Reduction in MIGS Procedures

NCT04202510 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-02-21

No results posted yet for this study

Summary

The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.

Conditions

  • Open Angle Glaucoma
  • Primary Open Angle Glaucoma
  • Pigmentary Glaucoma
  • Pseudoexfoliation Glaucoma in Both Eyes

Interventions

PROCEDURE

Glaucoma and Cataract Surgery

Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Daniel Lee, MD · Wills Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2020-11-12
Completion
2020-11-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202510 on ClinicalTrials.gov